Which medications in the drug class Monoclonal Antibodies, Anti-asthmatics are used in the treatment of Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome)?

Updated: Dec 24, 2018
  • Author: Spencer T Lowe, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Monoclonal Antibodies, Anti-asthmatics

Eosinophils produce proinflammatory mediators, such as eosinophilic cationic protein (ECP) and leukotrienes. IL-5 promotes eosinophil differentiation and activation, as well as trafficking into the lungs. Monoclonal antibodies against IL-5 have been developed to target eosinophilic inflammation.

Mepolizumab (Nucala)

Humanized IgG1 kappa monoclonal antibody specific for IL-5; binds IL-5, and therefore stops IL-5 from binding to its receptor on the surface of eosinophils. By inhibiting IL-5 signaling, mepolizumab reduces the production and survival of eosinophils.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!